AbbVie to Present 88% Five-Year Psoriatic Arthritis Nonprogression and 72.3% DLQI 0/1 Data
AbbVie will unveil 24 abstracts at the 2026 AAD meeting, including risankizumab five-year radiographic nonprogression in 88% of psoriatic arthritis patients and upadacitinib safety data spanning 9,000 patient-years. Real-world atopic dermatitis data showed 72.3% of patients achieving DLQI 0/1 and the company has increased dividends over 330% since 2013.
1. Robust Clinical and Real-World Dermatology Data
AbbVie will present 24 abstracts, including a late-breaking presentation, at the 2026 AAD Annual Meeting. Highlights include KEEPsAKE-1 Phase 3 five-year data showing 88% of patients with psoriatic arthritis had no radiographic progression through week 244, and upadacitinib safety across Measure Up and AD Up trials covering 2,683 patients and over 9,000 patient-years, with consistent adverse event rates and no major cardiovascular events in patients aged 12–49. Real-world AD-VISE data reported 72.3% of atopic dermatitis patients achieved DLQI 0/1 and over half reached EASI-90 in head and neck regions. Subgroup analyses from the IMMpactful trial showed risankizumab delivered PASI 90 in 57.3% vs 22.9% for deucravacitinib, and the Phase 4 UnlIMMited trial recorded DLQI 0/1 rates of 72%–88.9% in genital psoriasis and 83.3%–100% in scalp psoriasis, supporting the recent FDA prescribing information update.
2. Dividend Growth and Investor Yield Analysis
An analysis of AbbVie’s dividend policy shows a more than 330% increase in payouts since 2013, reflecting a robust pipeline and consistent revenue growth. The piece calculates the number of shares required to generate $10,000 in annual dividends at current rates, underscoring the company’s commitment to delivering shareholder returns.